According to the National Institute of Health, India’s Covaxin, developed by Bharat Biotech in conjunction with the Indian Council of Medical Research, efficiently neutralises both Alpha and Delta forms of coronavirus.
According to the NIH, two tests of blood serum from patients who received Covaxin show that the vaccine produces antibodies that successfully neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) forms of SARS-CoV-2, which were discovered in the United Kingdom and India, respectively.
The top American health research institute, which has a long history of scientific collaboration with India, also stated that an adjuvant developed with its funding contributed to the success of the highly effective Covaxin, which has been administered to approximately 25 million people in India and elsewhere.
Covaxin is made up of a crippled version of SARS-CoV-2 that cannot replicate but stimulates the immune system to produce antibodies against the virus. According to the NIH, published results from a phase 2 trial of the vaccine show that it is safe and well-tolerated and that safety data from a phase 3 trial of Covaxin will be available later this year.
“In the meantime, unpublished interim results from the phase 3 trial show that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalisation, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19,” the company said.
According to the NIH, “the results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, which were first identified in the United Kingdom and India, respectively.”
Ending a worldwide pandemic needs a global response, according to Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH).
“I am delighted that a new vaccine adjuvant developed in the United States with NIAID assistance is now included in an effective COVID-19 vaccination available to patients in India,” he added.
Continue Reading on Spot Latest